M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Gliosarcoma
Glioblastoma

Interventions: Drug: Atezolizumab
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2017-06-02

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 80

Registration Number: NCT03174197

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Phase 1

Active, not recruiting

Conditions: Malignant Solid Neoplasm
Malignant Breast Neoplasm
Malignant Colorectal Neoplasm
Malignant Pancreatic Neoplasm

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18-fluoroazomycin Arabinoside
Procedure: Positron Emission Tomography

First Posted Date: 2017-05-30

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25

Registration Number: NCT03168737

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Effect of Physician Attire on Patients' Preference of Physician

Not Applicable

Completed

Conditions: Malignant Neoplasms of Independent (Primary) Multiple Sites

Interventions: Behavioral: Video
Behavioral: Questionnaires

First Posted Date: 2017-05-30

Last Posted Date: 2020-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 108

Registration Number: NCT03168763

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer

Phase 2

Recruiting

Conditions: Recurrent Head and Neck Carcinoma

Interventions: Radiation: Stereotactic Body Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Radiation: Proton Radiation

First Posted Date: 2017-05-23

Last Posted Date: 2025-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03164460

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Selumetinib and Olaparib in Solid Tumors

Phase 1

Active, not recruiting

Conditions: Malignant Neoplasms of Digestive Organs
Malignant Neoplasms of Male Genital Organs
Malignant Neoplasms of Thyroid and Other Endocrine Glands
Malignant Neoplasm of Breast
Malignant Neoplasms of Female Genital Organs

Interventions: Drug: Selumetinib
Drug: Olaparib

First Posted Date: 2017-05-22

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT03162627

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Adenocarcinoma
Oligometastasis
Stage IV Esophageal Adenocarcinoma AJCC v7
Stage IV Esophageal Cancer AJCC v7
Stage IV Gastric Cancer AJCC v7

Interventions: Drug: Capecitabine
Drug: Chemotherapy
Procedure: Conventional Surgery
Drug: Fluorouracil
Radiation: Radiation Therapy

First Posted Date: 2017-05-19

Last Posted Date: 2025-05-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03161522

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Stage II Lung Non-Small Cell Cancer AJCC v7
Stage I Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7

Interventions: Biological: Ipilimumab
Drug: Carboplatin
Drug: Cisplatin
Biological: Nivolumab
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2017-05-17

Last Posted Date: 2025-03-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 101

Registration Number: NCT03158129

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

Not Applicable

Active, not recruiting

Conditions: Diseases of Liver
Liver Metastases
Colon Carcinoma
Colorectal Carcinoma

Interventions: Diagnostic Test: Computed Tomography Scan - 70% Dose Reduction
Diagnostic Test: Computed Tomography Scan - 50% Dose Reduction
Diagnostic Test: Deep Learning Image Reconstruction (DLIR)

First Posted Date: 2017-05-12

Last Posted Date: 2025-04-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 146

Registration Number: NCT03151564

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia With BCR-ABL1
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Biological: Filgrastim
Drug: Methotrexate
Biological: Pegfilgrastim
Drug: Ponatinib
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2017-05-10

Last Posted Date: 2025-02-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03147612

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Phase 1

Completed

Conditions: Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Biological: Durvalumab
Biological: Tremelimumab

First Posted Date: 2017-05-09

Last Posted Date: 2021-03-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT03144778

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy